Abstract
The topical calcineurin inhibitors — tacrolimus ointment 0.1 and 0.03% (FK 506, Protopic®, Astellas) and pime-crolimus cream 1% (SDZ ASM 981, Elidel®, Novartis) — have been specifically developed for the treatment of inflammatory skin diseases, and approved for the short-term and intermittent long-term treatment of atopic dermatitis in several countries (including the United States of America and European Union nations) [12, 19, 28, 32, 34, 38]. In contrast to topical steroid, they do not have the risk of local side effects, such as skin atrophy, telangiectasia, and glaucoma after prolonged use. Therefore, they are preferentially used in areas more susceptible to these side effects, such as head and neck region, flexures and genital area [23, 35]. Furthermore, because of the limited percutaneous penetration, signifi-cant systemic absorption has not been reported following normal use [1]. However, they are currently much more expensive than topical steroids.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allen A, Siegfried E, Silverman R et al (2001) Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 137:747–750
Almeida P, Borrego L, Rodriguez-Lopez J et al (2005) [Vitiligo. Treatment of 12 cases with topical tacrolimus]. Actas Dermosifiliogr 96:159–163
Bakos L, Bakos RM (2007) Focal acne during topical tac-rolimus therapy for vitiligo. Arch Dermatol 143:1223–1224
Bieber T, Cork M, Ellis C et al (2005) Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 211:77–78
Bilac DB, Ermertcan AT, Sahin MT, Ozturkcan S (2009) Two therapeutic challenges: facial vitiligo successfully treated with 1% pimecrolimus cream and 0.005% calcipot-riol cream. J Eur Acad Dermatol Venereol 23:72–73
Boone B, Ongenae K, Van Geel N et al (2007) Topical pime-crolimus in the treatment of vitiligo. Eur J Dermatol 17:55–61
Castanedo-Cazares JP, Lepe V, Moncada B (2003) Repigmentation of chronic vitiligo lesions by following tac-rolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed 19:35–36
Coskun B, Saral Y, Turgut D (2005) Topical 0.05% clobeta-sol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 15:88–91
Dawid M, Veensalu M, Grassberger M, Wolff K (2006) Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, doubleblind, vehicle-controlled study. J Dtsch Dermatol Ges 4:942–946
De D, Kanwar AJ (2008) Tacrolimus-induced hyperpigmen-tation in a patch of vitiligo. Skinmed 7:93–94
Fai D, Cassano N, Vena GA (2007) Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Dermatol Venereol 21:916–920
Fleischer AB, Ling M, Eichenfield L et al (2002) Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 47:562–570
Grimes PE, Morris R, Avaniss-Aghajani E et al (2004) Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 51:52–61
Grimes PE, Soriano T, Dytoc MT (2002) Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 47:789–791
Hartmann A, Brocker EB, Hamm H (2008) Occlusive t nhances efficay of tacrolimus 0.1% oinement in adult patients with vitiligo: results of a placebo-controlled 12 month prospective study. Acta Derm venereol 88:474–479
Kang HY, Choi YM (2006) FK506 increases pigmentation and migration of human melanocytes. Br J Dermatol 155:1037–1040
Kanwar AJ, Dogra S, Parsad D (2004) Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol 29:589–592
Kawalek AZ, Spencer JM, Phelps RG (2004) Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 30:130–135
Kostovic K, Pasic A (2005) New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs 65:447–459
Lan CC, Chen GS, Chiou MH et al (2005) FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 153:498–505
Lepe V, Moncada B, Castanedo-Cazares JP et al (2003) A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 139:581–585
Mayoral FA, Gonzalez C, Shah NS, Arciniegas C (2003) Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 207:322–323
Mayoral FA, Vega JM, Stavisky H et al (2007) Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo. J Drugs Dermatol 6:517–521
Mehrabi D, Pandya AG (2006) A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 142:927–929
Ormerod AD (2005) Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 153:701–705
Ostovari N, Passeron T, Lacour JP, Ortonne JP (2006) Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 142:252–253
Passeron T, Ostovari N, Zakaria W et al (2004) Topical tac-rolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 140:1065–1069
Qureshi AA, Fischer MA (2006) Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol 142:633–637
Sardana K, Bhushan P, Kumar Garg V (2007) Effect of tac-rolimus on vitiligo in absence of UV radiation exposure. Arch Dermatol 143:119–120
Seirafi H, Farnaghi F, Firooz A et al (2007) Pimecrolimus cream in repigmentation of vitiligo. Dermatology 214:253–259
Sendur N, Karaman G, Sanic N, Savk E (2006) Topical pimecrolimus: a new horizon for vitiligo treatment? J Dermatolog Treat 17:338–342
Silverberg NB, Lin P, Travis L et al (2004) Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 51:760–766
Smith DA, Tofte SJ, Hanifin JM (2002) Repigmentation of vitiligo with topical tacrolimus. Dermatology 205:301–303
Soter NA, Fleischer AB, Webster GF et al (2001) Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 44:S39–S46
Souza Leite RM, Craveiro Leite AA (2007) Two therapeutic challenges: periocular and genital vitiligo in children successfully treated with pimecrolimus cream. Int J Dermatol 46:986–989
Tanghetti EA () Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 71:158–162
Travis LB, Weinberg JM, Silverberg NB (2003) Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 139:571–574
Wolff K (2005) Pimecrolimus 1% cream for the treatment of atopic dermatitis. Skin Therapy Lett 10:1–6
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Van Geel, N., Boone, B., Mollet, I., Lambert, J. (2010). Calcineurin Inhibitors. In: Picardo, M., Taïeb, A. (eds) Vitiligo. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69361-1_39
Download citation
DOI: https://doi.org/10.1007/978-3-540-69361-1_39
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-69360-4
Online ISBN: 978-3-540-69361-1
eBook Packages: MedicineMedicine (R0)